Details of the Drug Combinations

General Information of This Drug (ID: DMHOSCQ)

Drug Name

Fruquintinib DMHOSCQ

Synonyms

HMPL-013

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fruquintinib + Rosuvastatin	DCS4W0D	Rosuvastatin	Metastatic Colorectal Cancer	[3]
Itraconazole + Fruquintinib	DCT8F95	Itraconazole	Drug Drug Interaction	[4]
Rifampicin + Fruquintinib	DCJYO0E	Rifampicin	Drug Drug Interaction	[4]
Fruquintinib + Irinotecan	DCT2NTC	Irinotecan	Gastric Cancer	[5]
Gefitinib + Fruquintinib	DC552OD	Gefitinib	NSCLC	[6]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217564
2	ClinicalTrials.gov (NCT02314819) A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients RESCO). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT05368805) Fruquintinib DDI Study With P-gp and BCRP Substrates
4	ClinicalTrials.gov (NCT04557397) Fruquintinib CYP3A Inhibitor and Inducer Study
5	ClinicalTrials.gov (NCT05643677) Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
6	ClinicalTrials.gov (NCT02976116) A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer